Que retenir dans la prise en charge des cancers en 2022 ?-Reference-Cited by-同舟云学术

Que retenir dans la prise en charge des cancers en 2022 ?

Published:2023-01 Issue:1 Volume:110 Page:19-31
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Bay Jacques-Olivier,Bouleuc Carole,Caux Christophe,Delom Frédéric,Firmin Nelly,Gandemer Virginie,L’Allemain Gilles,Magné Nicolas,Orbach Daniel,Robert Jacques,Rodrigues Manuel,Sabatier Renaud,Thiery-Vuillemin Antoine,Wislez Marie

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference78 articles.

1. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer;Cortés;N Engl J Med,2022

2. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022

3. Sacituzumab govitecan in metastatic triple-negative breast cancer;Bardia;N Engl J Med,2021

4. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer;Rugo;J Clin Oncol,2022

5. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response;Loibl;Ann Oncol,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot;Journal of Oncology Pharmacy Practice;2023-05-18

2. Note de l’Éditeur à propos de l’article « Que retenir dans la prise en charge des cancers en 2022 ? » [Bull Cancer 2023;110(1):19–31];Bulletin du Cancer;2023-03